Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye.

Bozdemir A, Hacıoğlu S, Akgün Çağlıyan G, Alayvaz Aslan N, Uzun SU, Kara K, Iltar U, Yücel OK, Ataş Ü, Arslan Kirezli S, Gemici Aİ, Alacacıoğlu İ, Yeniay MK, Bilgir O, Narlı Özdemir Z, Haydaroğlu Şahin H, Uysal A, Aksöz Z, Güven ZT, Aygün K, Tekinalp A, Yılmaz M, Atmaca Mutlu C, Pektaş G, Salim O, Güler N

Open source

DOI: 10.3390/jcm15166232
Published: 2026 Aug 12
Container: Journal of clinical medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/jcm15166232,
  title = {Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye.},
  author = {Bozdemir A and Hacıoğlu S and Akgün Çağlıyan G and Alayvaz Aslan N and Uzun SU and Kara K and Iltar U and Yücel OK and Ataş Ü and Arslan Kirezli S and Gemici Aİ and Alacacıoğlu İ and Yeniay MK and Bilgir O and Narlı Özdemir Z and Haydaroğlu Şahin H and Uysal A and Aksöz Z and Güven ZT and Aygün K and Tekinalp A and Yılmaz M and Atmaca Mutlu C and Pektaş G and Salim O and Güler N},
  year = {2026},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm15166232},
  url = {https://doi.org/10.3390/jcm15166232}
}

RIS

TY  - JOUR
TI  - Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye.
AU  - Bozdemir A
AU  - Hacıoğlu S
AU  - Akgün Çağlıyan G
AU  - Alayvaz Aslan N
AU  - Uzun SU
AU  - Kara K
AU  - Iltar U
AU  - Yücel OK
AU  - Ataş Ü
AU  - Arslan Kirezli S
AU  - Gemici Aİ
AU  - Alacacıoğlu İ
AU  - Yeniay MK
AU  - Bilgir O
AU  - Narlı Özdemir Z
AU  - Haydaroğlu Şahin H
AU  - Uysal A
AU  - Aksöz Z
AU  - Güven ZT
AU  - Aygün K
AU  - Tekinalp A
AU  - Yılmaz M
AU  - Atmaca Mutlu C
AU  - Pektaş G
AU  - Salim O
AU  - Güler N
PY  - 2026
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15166232
UR  - https://doi.org/10.3390/jcm15166232
ER  -

APA

A, B., S, H., G, A. Ç., N, A. A., SU, U., K, K., U, I., OK, Y., Ü, A., S, A. K., Aİ, G., İ, A., MK, Y., O, B., Z, N. Ö., H, H. Ş., A, U., Z, A., ZT, G., K, A., A, T., M, Y., C, A. M., G, P., O, S., & N, G. (2026). Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye.. Journal of clinical medicine. https://doi.org/10.3390/jcm15166232

Source records

pubmed · retrieved 2026-09-25T03:18:43.307Z